Israel's Entera Bio Q3 net loss widens
I'm PortAI, I can summarize articles.
Entera Bio reported a Q3 2025 net loss of $3.2 million, with increased operating expenses. Cash reserves are expected to support operations through mid-2026. Research and development expenses rose slightly to $1.6 million. The sole analyst rating is "buy," with a median 12-month price target of $10.00, significantly above the current price of $2.74.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments